Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10688MR)

This product GTTS-WQ10688MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10688MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5249MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ1741MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ9559MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ4945MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ12436MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ11704MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ14824MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ13077MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW